Menarini group and radius health, inc. announce publication of elacestrant pivotal phase 3 emerald clinical trial data in the journal of clinical oncology

Emerald study met both its primary end points of progression-free survival (pfs) in overall population and in esr1 mutated patients pfs rate at 12 months with elacestrant was 22.32% vs. 9.42% with soc in the overall population, and 26.76% vs.
RDUS Ratings Summary
RDUS Quant Ranking